活动期溃疡性结肠炎患者血小板功能与凝血纤溶功能的变化

目的研究活动期溃疡性结肠炎（ulcerative colitis,UC）患者的血小板功能及凝血纤溶功能的改变及其与病情严重程度的关系,并探讨各指标间变化的相关性。方法收集91例活动期UC住院患者与200名正常体检者进行血小板数量、血小板平均体积、凝血酶原时间、活化凝血酶原时间、D二聚体、纤维蛋白原检测,分别进行患病组与正常对照组、不同病情严重程度间的指标统计学分析,对差异具有统计学意义的指标进行相关性分析。结果活动期UC患者与正常对照组的血小板数量（P〈0.05）、血小板体积（P〈0.01）、D-二聚体（P〈0.01）和纤维蛋白原（P〈0.05）差异具有统计学意义,其余指标差异无统计学意义。根据病情严重程度不同,D二聚体的变化差异具有统计学意义。对差异具有统计学意义的指标进行相关性分析,D二聚体与纤维蛋白原的相关性高（r=0.586972）,并且具有统计学意义（P〈0.01）,另外血小板数量和纤维蛋白原的相关性也同样具有统计学意义（P〈0.01）,其余指标间无明显相关性。结论血小板数量、血小板体积、D二聚体、纤维蛋白原异常可作为疾病活动期的预测指标,D二聚体可随病情加重而增加。     

活动性炎症性肠病患者蛋白质和脂代谢的变化

目的 比较炎症性肠病患者及正常对照者之间蛋白质和脂代谢的差异,研究这些差异与疾病活动性及病变部位的关系.方法 回顾性研究1995至2007年溃疡性结肠炎(UC)195例、克罗恩病(CD)76例及正常对照者97名的蛋白质和脂代谢资料.同时评价临床疾病活动指数,红细胞沉降率(ESR)和C-反应蛋白(CRP)水平.性别分层分析蛋白质和脂代谢指标的改变,同时分析蛋白质和脂代谢的改变与疾病活动性及病变部位的关系.结果 UC患者的ESR与血清白球比呈负线性相关(β=-0.521,P＜0.01),与α2-球蛋白呈正线性相关(β=0.319,P＜0.01);CD患者血清球蛋白与ESR(β=0.558,P＜0.01)以及cRP(β=0.424,=P0.01)呈正线性相关.UC患者间因病变部位不同,血清白球比、白蛋白和总胆固醇水平存在显著差异,其中直乙结肠炎患者该三项显著高予其他类型的UC患者(P值分别=0.003、0.005、0.038).CD患者间亦因病变部位不同,血清球蛋白水平存在显著差异,仅累及结肠者的血清球蛋白水平显著高于单纯小肠受累者(P=0.029).结论 UC患者血清白球比和α2-球蛋白的异常程度可作为炎症活动性的预测因素;CD患者血清球蛋白增高预示疾病严重程度活动性增加,累及小肠的CD患者相对仅累及结肠的CD患者而言存在更为严重的营养缺失.     

炎症性肠病患者红细胞指数和血红蛋白的变化及其与疾病活动性的关系

目的 评价炎症性肠病患者及正常对照者之间红细胞指数和血红蛋白的差异及其与疾病活动性的关系.方法 队列研究271例炎症性肠病患者和正常对照者的红细胞指数和血红蛋白,分析红细胞指数和血红蛋白的改变和炎症活动性的关系.结果 克罗恩病患者血红蛋白浓度(P<0.01)、平均红细胞容积(P<0.05)、平均红细胞血红蛋白含量(P<0.01)和平均红细胞血红蛋白浓度(P<0.01)显著低于正常对照组;溃疡性结肠炎患者血红蛋门浓度和平均红细胞血红蛋白浓度显著低于正常对照组(P<0.01).相关分析表明,克罗恩病患者的血红蛋白浓度和克罗恩病活动指数(rs=-0.364,P=0.001)及红细胞沉降率(rs=-0.360,P=0.003)呈显著负相关;溃疡性结肠炎患者的血红蛋白浓度和红细胞沉降率呈显著负相关(rs=-0.565,P<0.001).结论 炎症性肠病患者的红细胞指数和血红蛋白发牛变化,其中血红蛋白浓度的变化和疾病的活动性呈负性相关.     

儿童炎症性肠病的临床表现和疾病表型

<正>儿童炎症性肠病(PIBD)分为溃疡性结肠炎(UC)、克罗恩病(CD)和炎症性肠病未定型(IBDU)3种。UC通常是累及直肠表面的炎症,并以连续方式延伸至邻近黏膜,CD的特点是透壁性炎症累及胃肠道的任何部位。IBDU是局限在结肠黏膜的炎症,其组织学特征在UC和CD之间无法区分[1]。PIBD因其发病机制复杂、临床表现多样且不典型     

炎症性肠病的肠外表现和并发症

<正>克罗恩病(CD)和溃疡性结肠炎(UC)都属于炎症性肠病(IBD)。IBD肠外表现的病因可能涉及到多种因素,有时候IBD的肠外表现(IBD本身累及其他器官)与IBD继发的肠外并发症(如营养不良、慢性炎症、药物的不良反应等所致)比较难鉴别。一般而言,IBD的肠外表现与IBD的活动性一致,但有些可能与IBD的活动性不一样,例如原发性硬化性胆管炎和强直性脊柱炎。这些肠外表现的症状可     

炎症性肠病的血栓前状态

炎症性肠病 (ＩＢＤ)包括溃疡性结肠炎 (ＵＣ)和克罗恩病 (ＣＤ) ,是与免疫过度反应有关的慢性肠道非特异性炎症 ,其病因目前尚未完全明了。ＩＢＤ的发病率在欧美地区国家较高 ,据欧洲炎症性肠病研究中心报道 ,ＵＣ发病率为 1 0 .4/1 0万 ,ＣＤ为5 .6/1 0万〔1〕。在亚洲 ,ＩＢＤ的发病率低于西方国家 ,但近 1 0～ 2 0年来呈上升趋势。ＩＢＤ患者与缺血性心脏病及糖尿病患者相似 ,也存在血栓并发症形成的潜在危险。青壮年及儿童易患 ,是造成病情恶化、导致死亡的重要原因。Ｇｒａｅｆ等 ( 1 966)报道的ＵＣ血栓栓塞症的死后尸检发生率高达39…     

糖尿病患者凝血与纤溶状态初探

我们对Ⅱ型糖尿病患者的部分凝血与纤溶指标的变化进行观察,并初步探讨这些变化的机制及意义。 一、一般资料 Ⅱ型糖尿病22例（男6,女16）,年龄20～70岁,平均49岁,均为住院患者。其中有糖尿病肾病或（和）血管并发症者12例;空腹血糖（FBG）<9mmol/L者7例,>9mmol/L者15例。正常对照25例（男14,女11）,年龄24～78岁,平均44岁。所有受检者1周内均未服用抗凝药物。 二、方法     

炎症性肠病结肠镜检查的评价

随着结肠镜对炎症性肠病镜下和活检病理形态改变的认识不断加深 ,它的使用价值也不断提高。Ｆｒ櫣ｈｍｏｒｇｅｎ总结过去 10年经验 ,发现对溃疡性结肠炎确诊率达 93.9% ,对克罗恩病达 77.3%。因此 ,近年来有倾向 ,结肠镜应列为诊断炎症性肠病的常规检查。结合我院过去 2 0年中炎症性肠病所见的形态改变 ,对其使用价值进行讨论。　　炎症性肠病在结肠镜下的形态 ,首先表现为分布方式和累及部位不同。溃疡性结肠炎呈连续性分布 ,并且疾病初期往往先累及直肠 ,逐渐向近端结肠蔓延 ,严重者累及整个结肠 ,仅有极少数倒灌性肠炎者可达回肠末端近…     

血清学标志物在监测炎症性肠病活动性中的研究现状

炎症性肠病(inflammatory bowel disease, IBD)是以胃肠道慢性炎症为特征的疾病,主要包括两种亚型,即克罗恩病(Crohn’s disease, CD)和溃疡性结肠炎(ulcerative colitis, UC)。内镜检查结合活检是用于IBD诊断和疾病管理最有效的方法,但其昂贵且具有侵入性,有肠穿孔和出血的风险。近年来研究人员在不断探索可替代的、非侵入性生物标志物作为监测IBD活动性和疾病管理的工具。血清学检测是一种成熟的诊断各种免疫性疾病的工具,其在IBD中的应用主要集中在确诊的患者身上,很少有人研究其作为疑似IBD患者主要诊断工具的潜力。本文介绍目前在IBD实验室检测中具有重要临床意义的非侵入性血清学标志物,这些血清学标志物可用于辅助诊断IBD并监测疾病的活动性,有助于临床医生精准把控疾病进展并及时调整治疗方案。     

对炎症性肠病诊断治疗规范的建议

炎症性肠病是一种病因尚不十分清楚的慢性非特异性肠道炎症性疾病 ,包括溃疡性结肠炎 (ＵＣ)和克罗恩病 (ＣＤ)。前者是一种慢性非特异性的结肠炎症 ,重者发生溃疡。病变主要累及结肠黏膜和黏膜下层。范围多自远段结肠开始 ,可逆行向近段发展 ,甚至累及全结肠及末段回肠 ,呈连续性分布。临床主要表现为腹泻、腹痛、黏液脓血便。后者病变可累及胃肠道各部位 ,而以末段回肠及其邻近结肠为主 ,为一种慢性肉芽肿性炎症 ,多呈节段性、非对称性分布。临床主要表现为腹痛、腹泻、瘘管、肛门病变和不同程度的全身症状。中华医学会消化病学分会曾先后…     

肠黏膜屏障与炎症性肠病

炎症性肠病（Innammatory bowel disease，IBD）是一组病因不明的慢性肠道炎症性疾病，主要包含两个独立的疾病，溃疡性结肠炎（Ulcerative colitis，UC）和克罗恩病（Crohn’s disease，CD）。近年研究发现，肠黏膜屏障功能异常在IBD发病机制中发挥重要作用。更好地了解正常及疾病状态下肠黏膜屏障的结构和功能可以为IBD的治疗提供新的思路。     

Roles of galectins in inflammatory bowel disease

Protein/carbohydrate interactions through specific protein families termed lectin control essential biological processes. Galectins, a family of animal lectins defined by shared amino acid sequence with affinity for β-galactosides, appear to be functionally polyvalent in a wide range of biological activity. Recent studies have identified immunoregulatory roles of galectins in intestinal inflammatory disorders. Galectin-1 and galectin -2 contribute to the suppression of intestinal inflammation by the induction of apoptosis of activated T cells, whereas galectin-4 is involved in the exacerbation of this inflammation by specifically stimulating intestinal CD4＋ T cells to produce IL-6. We review how different members of the galectins provide inhibitory or stimulatory signals to control intestinal immune response under intestinal inflammation.     

Obesity and novel management of inflammatory bowel disease

Obesity is prevalent within the inflammatory bowel disease(IBD) population,particularly in newly developed countries.Several epidemiological studies have suggested that 15%-40% of IBD patients are obese,and there is a potential role of obesity in the pathogenesis of IBD.The dysfunction of mesenteric fat worsens the inflammatory course of Crohn’s disease and may induce formation of strictures or fistulas.Furthermore,obesity may affect the disease course or treatment response of IBD.Given the incr...     

炎症性肠病相关性肝病的研究进展

炎症性肠病(inflammatory bowel disease,IBD)是一种累及回肠、结肠、直肠的特发性炎症性疾病,本病主要包括溃疡性结肠炎(ulcerative colitis,UC)和克罗恩病(Crohn’s disease,CD)。除常见的消化道症状外,研究发现IBD合并肝脏疾病较为常见,是IBD常见的肠外表现之一,其严重影响IBD的预后与转归。本文就IBD相关性肝病的分类和总结作一概述,以期为IBD及其肝脏病变的临床诊疗提供参考。     

营养与炎症性肠病

营养和炎症性肠病的发病机制及治疗有密切的关系,深入研究两者的关系对临床有重要的意义。此文对饮食中的营养成分是否和发病有关、如何营养支持等问题作一简要概述。     

肠易激综合征与炎症性肠病

近年发现,炎症性肠病(IBD)患者发病早期或缓解期时常表现为肠易激综合征(IBs)症状,且IBD与IBS的临床表现具有一定的相似性。因而IBS与IBD的相关性受到广泛的重视。此文就IBS与IBD的发病机制及临床相关性予以阐述,以期为临床个体化治疗提供借鉴。     

Patient preferences for inflammatory bowel disease treatment objectives

BackgroundThere is currently little evidence about what treatment objectives most interest patients with inflammatory bowel disease (IBD).AimsTo determine patient preferences regarding IBD treatment objectives, specially the attributes they value most and the symptoms to be controlled as a priority.MethodsProspective, observational, anonymous study conducted in 117 outpatients with Crohn’s disease or ulcerative colitis.ResultsThe most important treatment objectives from the patients’ perspective were: improving quality of life (40.2% of patients), and completely resolving symptoms (33.3%). Only 12.8% of patients indicated having a completely normal colonoscopy as a preferred objective. The symptoms the patients considered to be most important when prioritizing their control were: abdominal pain (23.1% of patients), and bowel movement urgency (17.1%). The preferred treatment objectives were similar for Crohn’s disease and ulcerative colitis patients.ConclusionsImproving quality of life and completely controlling symptoms are the priority treatment objectives for IBD patients, with abdominal pain being the most important symptom. Conversely, therapeutic objective target goals proposed by physicians, such as healing the mucosal lesions, are not a priority for most patients. This indicates that there are discrepancies between patient and physician expectations, which should be taken into account if a patient-centered care model is to be implemented.     

炎症性肠病血浆Prickle1水平的鉴别意义

目的 研究炎症性肠病患者血浆Prickle1水平对于鉴别诊断的价值.方法 应用酶联免疫吸附试验(Enzyme-Linked ImmunoSorbent Assay,ELISA)分析克罗恩病患者、溃疡性结肠炎患者和正常对照者血浆中Prickle1蛋白的表达.受试者工作特征曲线(receiver-operating cha...     

Dysplasia and colorectal cancer surveillance in inflammatory bowel disease

Introduction: Inflammatory bowel disease (IBD) patients are at an increased risk of developing colorectal cancer (CRC), a devastating complication of which intestinal dysplasia is the precursor. Considerable progress has been made to determine CRC risk in IBD, identification & management of dysplasia and preventative methods. Traditionally, surveillance colonoscopies with random colonic biopsies was used. However recent data suggests that chromoendoscopy is a better method of surveillance. Using 5-aminosalicylic acid agents primarily for chemoprevention is an ongoing debate however, when prescribed along with other strategies to control inflammation, their use is considered of benefit. This review presents current understanding of risk factors of neoplasia focusing on dysplasia and preventive strategies.

Areas covered: PubMed search was done using key words to assess current evidence. Along with genetics, risk factors, strategies that modify the risk of dysplasia, and CRC in IBD are discussed in detail.

Expert commentary: The role of our strategies in modifying CRC risk needs further assessment. Future research should aim to fill knowledge gaps such as high quality evidence for Chromoendoscopy and development of molecular markers for dysplasia detection. Our ultimate goal would be to eliminate CRC and is possible by better understanding of key pathogenic mechanisms in IBD.     

Effectiveness and safety of vedolizumab for maintenance treatment in inflammatory bowel disease—The Israeli real world experience

Introduction

Several real-world experience (RWE) studies with vedolizumab (VDZ) for induction of remission in inflammatory bowel diseases (IBD) have been published; however, long-term RWE data is scarce.